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ABSTRACT
Objective: Even previous reports mentioned that thyroxine has beneficial effects on subclinical hypothyroidism (SCH); however, the mechanism 
by which thyroxine mediated such effect still unclear. Thus, we aim to find out the potential benefit of thyroxine administration in women with SCH 
through assessment of lipids profile with evaluation of uterine and ovarian blood flow indexes.
Patients and Methods: The current study included 80 women with SCH who had a history of recurrent intrauterine death. Those women were 
chosen from the cohort of pregnant ladies that routinely seek medical advice. For each woman, estimation of serum thyroid-stimulating hormone 
(TSH), serum lipids profile (low-density lipoprotein [LDL], total cholesterol [TC], and triglyceride [TG]), and also uterine and ovarian pulsatile index 
(PI) and resistance index (RI) using color Doppler ultrasound, was done at the beginning of study and then repeated following 2 months during which 
women were given oral thyroxine supplementation (50 μg/d). The study was carried out in Al-Diwaniyah Maternity and Child Teaching Hospital in 
Al-Diwaniyah province, Iraq and extended from September 2016 to January 2018.
Results: Mean serum TSH, LDL, TG, and TC were significantly reduced (p<0.05). Mean early follicular phase ovarian RI and PI and uterine RI were 
significantly reduced (p<0.05). In addition, mean late follicular phase ovarian RI and PI and uterine RI were significantly reduced (p<0.05).
Conclusion: Thyroxine administration to women with SCH significantly decreases serum lipids and increases uterine and ovarian blood flow by 
mechanism involving reduction in arterial RI and PI.
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INTRODUCTION
Thyroid disorders are seen frequently during pregnancy and briefly 
following labor. The second most frequent endocrine disorder affecting 
women throughout reproductive age is thyroid disease [1,2]. The 
chemical structure of human chorionic gonadotropin (HCG) is similar 
to that of thyroid-stimulating hormone (TSH), thus HCG is able to both 
stimulate the thyroid gland with subsequent increase in thyroxine 
hormone level [3]. The usual presentation of thyroid abnormality in 
women during pregnancy is high TSH and lower normal or sometimes 
even low thyroxine during the first trimester of pregnancy [4]. Women 
hypothyroidism has been accompanied by higher risk of reduced 
birth weight, altered neuropsychological maturation, fetal distress, 
and intrauterine death [5-7]. It has been suggested that women with 
clinical and subclinical hypothyroidism (SCH) must be given thyroxine 
throughout pregnancy to keep serum TSH within the desired reference 
range [4].
Uterine blood flow is increased up to 20-fold during normal pregnancy, 
and this has been regarded as a normal physiological response to 
maintain the growing fetus [8]. Nowadays, a color Doppler ultrasound 
technique is used to assess the uterine and ovarian blood flow 
depending on two indexes: The “pulsatile index (PI) and resistance 
index (RI)” that are negatively proportional to impedance to blood 
flow and this technique is regarded as an efficient way to evaluate both 
ovarian and uterine blood flow inadequacy [9-11].
Significant changes in serum lipids profile have accompanied SCH. 
Many published articles documented the high serum low-density 
lipoprotein (LDL), triglycerides (TGs), and total cholesterol (TC) in 
individuals suffering from hypothyroidism [12-14]. It has been shown 
that during pregnancy, TC, LDL, high-density lipoprotein (HDL), and 
TGs get rise [15]. Hypercholesterolemia that accompanies pregnancy is 
attributable also to alterations in liver metabolism, adipose metabolism, 
and sex steroid hormones [16]. Women with hyperlipidemia are 
associated with adverse fetal and maternal outcome and increased risk 
of premature labor and intrauterine death [17-19].
Hence, the aim of the present study was to evaluate the effect of 
thyroxine administration to women with SCH and who had a history 
of recurrent intrauterine fetal death through uterine and ovarian 
ultrasound blood flow estimation and serum lipids profile assessment 
before and after 2 months of treatment.
PATIENTS AND METHODS
The current study included 80 women with SCH who had a history of 
recurrent intrauterine death. Those women were chosen from the cohort 
of pregnant ladies that routinely seek medical advice. For each woman, 
estimation of serum TSH, serum lipids profile (LDL, TC, and TG), and 
also uterine and ovarian PI and RI using color Doppler ultrasound, was 
done at the beginning of study and then repeated following 2 months 
during which women were given oral thyroxine supplementation. The 
study was carried out in Al-Diwaniyah maternity and child teaching 
hospital in AL-Diwaniyah Province, Iraq and extended from September 
2016 to January 2018.
Statistical analysis was carried out using SPSS version 23.0 and 
Microsoft Office Excel 2010. Nominal data were expressed as numbers 
and percentages while numeric data were expressed as mean and 
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standard deviation. Paired t-test was used to compare mean differences 
in serum TSH, LDL, TG, TC, ovarian, and uterine PI and RI. The level of 
statistical significance was considered at p≤0.05.
RESULTS
Mean serum TSH was significantly reduced from 7.35±0.97 to 
3.81±0.52 mIU/L (p<0.05). Mean serum LDL was significantly reduced 
from 175.45±8.22 to 123.05±7.65 mg/dl (p<0.05). Mean serum TG 
was significantly reduced from 296.50±46.23 to 146.60±12.25 mg/dl 
(p<0.05). Mean serum TC was significantly reduced from 281.10±17.40 
to 174.60±12.87 mg/dl (p<0.05), as shown in Fig. 1.
Mean early follicular phase ovarian RI was significantly reduced from 
0.74±0.03 to 0.67±0.02 (p<0.05). Mean early follicular phase ovarian 
PI was significantly reduced from 2.51±0.17 to 2.10±0.18 (p<0.05). 
Mean early follicular phase uterine RI was significantly reduced from 
2.31±0.14 to 1.84±0.15 (p<0.05), as shown in Fig. 2.
Mean late follicular phase ovarian RI was significantly reduced from 
0.67±0.03 to 0.58±0.02 (p<0.05). Mean late follicular phase ovarian 
PI was significantly reduced from 16.55±1.36 to 12.45±0.89 (p<0.05). 
Mean late follicular phase uterine PI was significantly reduced from 
2.63±0.13 to 2.02±0.08 (p<0.05), as shown in Fig. 2.
DISCUSSION
The present study showed that administration of thyroxine to women 
with SCH caused significant improvement in both ovarian and uterine 
blood flow as evident by significant lower mean PI and mean RI. In 
addition, the current study showed significant improvement in serum 
lipids profile of the women following thyroxin treatment.
The most frequent pathological hormone insufficiency is primary 
hypothyroidism, and the rate of subclinical and clinical disease is 
4.3% and 0.3%, respectively [20]. Inadequacy of thyroid hormones 
results in a number of significant end-organ outcomes that also include 
reproductive system defects of the women. Prolonged hypothyroid 
status can alter gonadotropin production by raising serum prolactin 
(PRL) concentrations [21]. Clinical features, including impaired fertility 
and menstrual irregularities, are the consequence of “anovulation and/
or luteal phase defect” [22].
Most women with hypothyroidism will develop amenorrhea. 
Reproductive disorders that accompany hypothyroidism include 
wide spectrum of abnormalities ranging from altered sexual 
maturation, irregular menstruation, and subfertility [23]. The effect of 
hypothyroidism on menstruation has been observed since the 1950s and 
is associated with alterations in cycle duration and blood amount [23]. 
SCH has been seen to be correlated with occult menorrhagia that 
becomes symptomatic later with the progression of thyroid illness [24]. 
Hypothyroidism causes an elevation in the levels of thyroid-releasing 
hormone which, in turn, stimulates secretion of TSH and PRL and 
PRL inhibits the synthesis and secretion of gonadotrophins [25]. It 
was observed that thyroid receptors are also found in ovarian surface 
epithelium and affect ovarian follicles, in addition to their existence in 
granulosa cells of ovarian follicles [26]. It has been seen that thyroxine 
controls a number of biological functions including cellular oxygen 
consumption, growth, embryonic development, cellular metabolism, 
and tissue maturation and differentiation [27].
Serum concentrations of LH and FSH are profoundly low in women with 
clinically symptomatic hypothyroidism when estimated between day 2 
and 5 of the menstrual cycle [28]. Studies have demonstrated that serum 
estradiol was also reduced significantly in the hypothyroid state when 
compared to the control [29]. Studies have demonstrated a positive 
correlation in between TSH and PRL in hypothyroid women [30]. In 
many studies, it was shown that T4 administration in hypothyroidism 
normalizes PRL and LH levels, increases folliculogenesis and estradiol 
secretion, reverses menstrual abnormalities, and increases spontaneous 
fertility [31].
Uterine blood flow alternates along with alterations in the steroid levels 
throughout the length of the menstrual cycle and also during pregnancy. 
At time of follicular phase of the cycle that is typified by an elevated 
“estrogen-to-progesterone ratio,” uterine blood flow becomes high. 
At time of the incoming luteal phase that is characterized by greater 
progesterone and less estrogen, uterine blood flow is low. On the other 
hand, at time of pregnancy that is characterized by greater estrogen 
and progesterone, uterine blood flow will increase and the increment 
is rising with advancing pregnancy. Because uterine blood flow 
patterns change along with the steroid hormone profile, many studies 
are focused on the ways by which these blood vascular responses are 
induced. Estradiol-17β (E2β) is a strong blood vessel dilator agent that 
has been utilized to evaluate ovarian steroid hormone actions on blood 
flow parameters [32].
Thyroid hormones play an important role in synthesis, mobilization, 
and metabolism of lipids [33]. Therefore, hypothyroidism is a major 
Fig. 1: Mean serum thyroid-stimulating hormone and lipids profile of pregnant women before and after thyroxin treatment
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cause of secondary dyslipidemia. Investigations report elevated levels 
of TC and LDL in patients with overt hypothyroidism. Those patients 
may also present elevated to normal levels of TG and HDL [34,35]. In 
SCH, there is an elevation in TSH with normal levels of thyroxine (T4) 
and tri-iodothyronine (T3) [14,36].
In conclusion, thyroxine administration to women with SCH significantly 
increases uterine and ovarian blood flow and decreases serum lipids.
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